Association of antithrombotic drug use with subdural hematoma risk

JAMA - Journal of the American Medical Association

Volumn 317, Issue 8, 2017, Pages 836-846

  Gaist, David ^a,b   Garcia Rodriguez, Luis Alberto ^c   Hellfritzsch, Maja ^d   Poulsen, Frantz Rom ^a,b   Halle, Bo ^a   Hallas, Jesper ^d   Pottegard, Anton ^d  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c Centro Espanol Investigation Farmacoepidemiologica   (Spain)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; TICLOPIDINE; VITAMIN K GROUP;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE CONTROL STUDY; COMBINATION DRUG THERAPY; DENMARK; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SUBDURAL HEMATOMA; TREND STUDY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMORBIDITY; HEMATOMA, SUBDURAL; MIDDLE AGED; ODDS RATIO; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; CASE-CONTROL STUDIES; COMORBIDITY; DENMARK; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMATOMA, SUBDURAL; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE; VITAMIN K; YOUNG ADULT;

EID: 85014637006     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.0639     Document Type: Article

References (30)

1. Adhiyaman V, Asghar M, Ganeshram KN, Bhowmick BK. Chronic subdural haematoma in the elderly. Postgrad Med J. 2002;78(916):71-75.
2. Balser D, Farooq S, Mehmood T, ReyesM, Samadani U. Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations. J Neurosurg. 2015;123(5):1209-1215.
3. Pedersen K, Fahlstedt M, Jacobsson A, Kleiven S, von Holst H. A national survey of traumatic brain injuries admitted to hospitals in Sweden from 1987 to 2010. Neuroepidemiology. 2015;45(1):20-27.
4. Connolly BJ, Pearce LA, Kurth T, Kase CS, Hart RG. Aspirin therapy and risk of subdural hematoma: meta-analysis of randomized clinical trials. J Stroke Cerebrovasc Dis. 2013;22(4):444-448.
5. Connolly BJ, Pearce LA, Hart RG. Vitamin K antagonists and risk of subdural hematoma: meta-analysis of randomized clinical trials. Stroke. 2014;45(6):1672-1678.
6. De Bonis P, Trevisi G, deWaure C, et al. Antiplatelet/anticoagulant agents and chronic subdural hematoma in the elderly. PLoS One. 2013; 8(7):e68732.
7. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333(7571):726.
8. Thygesen LC, Daasnes C, Thaulow I, Bronnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 2011;39(7)(suppl):12-16.
9. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7)(suppl):30-33.
10. Rothman K, Greenland S, Lash T. Modern Epidemiology. 3rd ed. Philadelphia, PA:Wolters Kluwer Health, Lippincott Williams & Wilkins; 2008.
11. Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7)(suppl): 22-25.
12. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4): 445-448.
13. World Health Organization. Guidelines for ATC classification and DDD assignment. https://www.whocc.no/atc-ddd-index/. Accessed January 31, 2017.
14. Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011;39(7)(suppl): 91-94.
15. Poulsen FR, Halle B, Pottegard A, Garcia Rodriguez LA, Hallas J, Gaist D. Subdural hematoma cases identified through a Danish patient register: diagnosis validity, clinical characteristics, and preadmission antithrombotic drug use. Pharmacoepidemiol Drug Saf. 2016;25(11):1253-1262.
16. Statistics Denmark. http://www.statistikbanken.dk.AccessedFebruary1,2016.
17. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1(7138):1309-1312.
18. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
19. Baigent C, Blackwell L, Collins R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborativemeta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860.
20. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
21. Larsen TB, Skjoth F, Nielsen PB, Kjaldgaard JN, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
22. Reymond MA, Marbet G, Radu EW, Gratzl O. Aspirin as a risk factor for hemorrhage in patients with head injuries. Neurosurg Rev. 1992;15(1):21-25.
23. Baechli H, Nordmann A, Bucher HC, Gratzl O. Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study. Neurosurg Rev. 2004;27 (4):263-266.
24. Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci. 2006;13 (8):823-827.
25. Lindvall P, Koskinen L-OD. Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas. J Clin Neurosci. 2009;16(10):1287-1290.
26. Hart RG, Diener H-C, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511-1517.
27. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120(8): 700-705.
28. Adelborg K, Grove EL, Sundboll J, Laursen M, Schmidt M. Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. Heart. 2016;102 (23):1883-1889.
29. Medstat. Statistics on the total sales of medicines in Denmark 1996-2015. http://medstat.dk/en.AccessedFebruary 15, 2016.
30. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897-902.